mTOR inhibitors in pediatric kidney transplantation

Area of Science:

• Nephrology
• Immunosuppression
• Pediatric Transplantation

Background:

• Mammalian target of the rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, are increasingly utilized in pediatric kidney transplantation.
• Previous research indicates beneficial effects of mTOR inhibitors in children post-renal transplant.

Purpose of the Study:

• To evaluate the efficacy and safety of mTOR inhibitors in pediatric kidney transplant recipients.
• To assess the impact of mTOR inhibitors, particularly in combination with low-dose calcineurin inhibitors (CNIs), on graft survival, rejection rates, and side effects.

Main Methods:

• Review of studies investigating mTOR inhibitors in pediatric kidney transplantation.
• Analysis of outcomes including glomerular filtration rate (GFR), graft survival, rejection incidence, and adverse events.
• Comparison of different dosing strategies and combinations with CNIs.

Main Results:

• Switching to a low-dose CNI and mTOR inhibitor combination stabilizes GFR.
• De novo therapy with low-dose CNI and mTOR inhibitors demonstrates good graft survival and low rejection rates.
• Lower doses of mTOR inhibitors, especially when combined with CNIs, minimize side effects like hyperlipidemia and proteinuria, and do not cause growth impairment or reduced testosterone levels.
• mTOR inhibitors are associated with fewer viral infections, particularly cytomegalovirus, and may reduce the risk of post-transplant lymphoproliferative disease due to their antiproliferative properties.

Conclusions:

• mTOR inhibitors, particularly in combination with low-dose CNIs, can be safely administered as de novo therapy or for conversion in pediatric kidney transplant patients.
• This therapeutic approach offers a favorable balance of efficacy and safety, supporting stable graft function and reducing adverse events.